Complete Remission of Metastatic and Relapsed Uterine Cervical Cancers Using Weekly Administration of Bevacizumab and Paclitaxel/Carboplatin

Onkologie

Volumn 32, Issue 10, 2009, Pages 595-597

  Takano, Masashi ^a   Kikuchi, Yoshihiro ^b   Kita, Tsunekazu ^c   Goto, Tomoko ^d   Yoshikawa, Tomoyuki ^a   Kato, Masafumi ^a   Watanabe, Akio ^a   Sasaki, Naoki ^a   Miyamoto, Morikazu ^a   Inoue, Hiromi ^e   Ohbayashi, Miki ^e  

^a NATIONAL DEFENSE MEDICAL COLLEGE   (Japan)

^b Ohki Memorial Kikuchi Cancer Clinic for Women   (Japan)

^c TEIKYO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^d SAITAMA MEDICAL UNIVERSITY   (Japan)

^e SHONAN KAMAKURA GENERAL HOSPITAL   (Japan)

Author keywords

Bevacizumab; Cervical cancer; Paclitaxel Carboplatin; Recurrence; Weekly administration

Indexed keywords

BEVACIZUMAB; CARBOPLATIN; CISPLATIN; DOCETAXEL; GEMCITABINE; PACLITAXEL;

ADULT; ARTICLE; BLOOD TOXICITY; CANCER COMBINATION CHEMOTHERAPY; CANCER REGRESSION; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; FEMALE; HUMAN; METASTASIS; MULTIPLE CYCLE TREATMENT; NUCLEAR MAGNETIC RESONANCE IMAGING; SALVAGE THERAPY; SQUAMOUS CELL CARCINOMA; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; UTERINE CERVIX CANCER; UTERINE CERVIX CARCINOMA;

ADULT; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PACLITAXEL; REMISSION INDUCTION; TREATMENT OUTCOME; UTERINE NEOPLASMS;

EID: 70350751574     PISSN: 0378584X     EISSN: None     Source Type: Journal    
DOI: 10.1159/000232554     Document Type: Article

References (17)

1. Stewart BW, Kleihues P: World Cancer Report. Lyon, IARC Press, 2003.
2. Moore DH, Blessing JA, McQuellon RP, Thaler HT, Cella D, Benda J, Miller DS, Olt G, King S, Boggess JF, Rocereto TF: Phase III study of cisplatin with or without paclitaxel in stage IVB, recurrent, or persistent squamous cell carcinoma of the cervix: A Gynecologic Oncology Group study. J Clin Oncol 2004;22:3113-3119.
3. Long HJ 3rd, Bundy BN, Grendys EC Jr, Benda JA, McMeekin DS, Sorosky J, Miller DS, Eaton LA, Fiorica JV; Gynecologic Oncology Group Study: Randomized phase III trial of cisplatin with or without topotecan in carcinoma of the uterine cervix: A Gynecologic Oncology Group study. J Clin Oncol 2005;23:4626-4633.
4. duPont NC, Monk BJ: Chemotherapy in the management of cervical carcinoma. Clin Adv Hematol Oncol 2006;4:279-286.
5. du Bois A, Lück HJ, Meier W, Adams HP, Möbus V, Costa S, Bauknecht T, Richter B, Warm M, Schröder W, Olbricht S, Nitz U, Jackisch C, Emons G, Wagner U, Kuhn W, Pfisterer J; Arbeitsgemeinschaft Gynäkologische Onkologie Ovarian Cancer Study Group: A randomized clinical trial of cisplatin/ paclitaxel versus carboplatin/paclitaxel as firstline treatment of ovarian cancer. J Natl Cancer Inst 2003;95:1320-1329.
6. Ozols RF, Bundy BN, Greer BE, Fowler JM, Clarke-Pearson D, Burger RA, Mannel RS, De- Geest K, Hartenbach EM, Baergen R; Gynecologic Oncology Group: Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: A Gynecologic Oncology Group study. J Clin Oncol 2003;21:3194-3200.
7. Sit AS, Kelley JL, Gallion HH, Kunschner AJ, Edwards RP: Paclitaxel and carboplatin for recurrent or persistent cancer of the cervix. Cancer Invest 2004; 22:368-373.
8. Moore KN, Herzog TJ, Lewin S, Giuntoli RL, Armstrong DK, Rocconi RP, Spannuth WA, Gold MA: A comparison of cisplatin/paclitaxel and carboplatin/ paclitaxel in stage IVB, recurrent or persistent cervical cancer. Gynecol Oncol 2007;105:299-303.
9. Mori T, Hosokawa K, Kinoshita Y, Watanabe A, Honjo H: Neoadjuvant chemotherapy with weekly carboplatin and paclitaxel for locally advanced cervical carcinoma. Int J Gynecol Cancer 2008;18:85-89.
10. Wright JD, Hagemann A, Rader JS, Viviano D, Gibb RK, Norris L, Mutch DG, Powell MA: Bevacizumab combination therapy in recurrent, platinum- refractory, epithelial ovarian carcinoma: A retrospective analysis. Cancer 2006;107:83-89.
11. Cannistra SA, Matulonis UA, Penson RT, Hambleton J, Dupont J, Mackey H, Douglas J, Burger RA, Armstrong D, Wenham R, McGuire W: Phase II study of bevacizumab in patients with platinum- resistant ovarian cancer or peritoneal serous cancer. J Clin Oncol 2007;25:5180-5186.
12. Van Trappen PO, Steele D, Lowe DG, Baithun S, Beasley N, Thiele W, Weich H, Krishnan J, Shepherd JH, Pepper MS, Jackson DG, Sleeman JP, Jacobs IJ: Expression of vascular endothelial growth factor (VEGF)-C and VEGF-D, and their receptor VEGFR-3, during different stages of cervical carcinogenesis. J Pathol 2003;201:544-554.
13. Soufla G, Sifakis S, Baritaki S, Zafiropoulos A, Koumantakis E, Spandidos DA: VEGF, FGF2, TGFB1 and TGFBR1 mRNA expression levels correlate with the malignant transformation of the uterine cervix. Cancer Lett 2005;221:105-118.
14. Lee IJ, Park KR, Lee KK, Song JS, Lee KG, Lee JY, Cha DS, Choi HI, Kim DH, Deung YK: Prognostic value of vascular endothelial growth factor in stage IB carcinoma of the uterine cervix. Int J Radiat Oncol Biol Phys 2002;54:768-779.
15. Noriyuki M, Sumi T, Zhi X, Misugi F, Nobeyama H, Yoshida H, Matsumoto Y, Yasui T, Honda K, Ishiko O: Vascular endothelial growth factor, matrix metalloproteinases, and cyclooxygenase-2 influence prognosis of uterine cervical cancer in young women. Int J Oncol 2007;31:531-536.
16. Sandler A, Gray R, Perry MC, Brahmer J, Schiller JH, Dowlati A, Lilenbaum R, Johnson DH: Paclitaxel- carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 2006;355: 2542-2550.
17. Klement G, Huang P, Mayer B, Green SK, Man S, Bohlen P, Hicklin D, Kerbel RS: Differences in therapeutic indexes of combination metronomic chemotherapy and an anti-VEGFR-2 antibody in multidrug-resistant human breast cancer xenografts. Clin Cancer Res 2002;8:221-232.